The CSN 2022 Webinar Series are supported by an unrestricted educational grant from Glaxo Smith Kline.

Hit or Myth: New Advances in the Management of Hyperkalemia and Hyperphosphatemia

DOWNLOAD A PDF OF THE PRESENTATION
The presentation and slides have been shared with you by the speaker(s) on behalf of the CSN. Reproduction and distribution of the recording and/or presentation without written permission from the speaker(s) or the CSN is prohibited. If you wish to use the slides, please send your request to info@csnscn.ca for approval.

Challenge your knowledge and join Canadian experts for this engaging and innovative Section 3 program!

Prepare to apply clinical efficacy and safety data on new potassium and phosphate binders to reduce the impact of hyperkalemia or hyperphosphatemia in your patients with CKD.

A personalized action plan will provide you with strategies on the use of the new potassium and phosphate binders in patients with hyperkalemia or hyperphosphatemia and allows you to earn three Section 3 credits in real time.

Learning Objectives

Upon completion of this program, participants will be able to:

  • Apply the epidemiologic data as well as outcome data of hyperkalemia and hyperphosphatemia to your local practice
  • Integrate knowledge of recent clinical trials, practice patterns, and available therapies into your management of hyperkalemia and hyperphosphatemia.
  • Apply clinical efficacy and safety data on new potassium and phosphate binders to reduce the impact of hyperkalemia or hyperphosphatemia
  • Implement RAASi enablement strategies in patients at risk of or with chronic hyperkalemia

Section 2 – Self Learning Credits
For information on how this activity fits in the Royal College Maintenance of Certification (MOC) Program, please visit the Royal College’s website (royalcollege.ca/moc). For more personalized support, please contact the Royal College Services Centre(1-800-461-9598) or your local CPD Educator.

EXPERT PANELISTS


Juliya Hemmett, MD, MHPE, FRCPC (Moderator)

Nephrologist and Clinical Assistant Professor
University of Calgary



Louis-Philippe Girard, MD, MBT, FRCPC

Medical Director of Apheresis
Medical Director of the Glomerulonephritis Clinic
Nephrologist and Clinical Associate Professor
University of Calgary



Louise Moist, MD, FRCPC

Professor of Medicine Epidemiology and Biostatistics
Nephrologist, London Health Sciences Centre
Deputy Chair Division of Nephrology
South West LHIN Internal Medicine Lead
Schulich School of Medicine & Dentistry, Western University

This program is being supported by an unrestricted educational grant from Otsuka Canada Pharmaceutical Inc.